Abstract
Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Anti-Infective Agents
Title:Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis
Volume: 10 Issue: 2
Author(s): Azam J. Samdani, Samreen, M. Iqbal Choudhary and Atta-ur-Rahman
Affiliation:
Keywords: Leishmaniasis, cutaneous leishmaniasis, clinical trials, garlic extract, topical applications, anti-leishmanial activity, In vitro studies
Abstract: Leishmaniasis is a global disease, which has become a major health challenge for Pakistan and other developing countries. Infections caused by the parasitic protozoa constitute a major hindrance in socioeconomic development in many developing countries. In this study, we developed a topical application (gel), containing active ingredients derived from garlic, on which in vitro, in vivo, and clinical studies were conducted. Anti-leishmanial activity observed in vitro was followed by in vivo study with the application of this active ingredient, prepared in gel form, and applied once daily on experimental mouse model. Their lesions cured completely within 4-6 weeks. This was followed by clinical trials in humans. A total of 70 patients, 58 (82.85%) males, and 12 (17.14%) females, were selected with positive Leishmania parasites by smear examination. Out of 70 patients, 57 patients (81.42%) responded to the treatment, while 13 patients (18.57%) did not. Ten patients (17.54%) showed complete clinical recovery after 06 weeks of therapy, while 40 (70.17%) showed complete clinical recovery after 08 weeks of therapy. The results of this clinical study establish the efficacy, and cost effectiveness of garlic-based topical gel, and pave the way for further research in its therapeutic applications.
Export Options
About this article
Cite this article as:
J. Samdani Azam, Samreen , Iqbal Choudhary M. and Atta-ur-Rahman , Laboratory Studies and Clinical Trials on New Formulations from Garlic Extract Against Cutaneous Leishmaniasis, Anti-Infective Agents 2012; 10 (2) . https://dx.doi.org/10.2174/2211362611208020111
DOI https://dx.doi.org/10.2174/2211362611208020111 |
Print ISSN 2211-3525 |
Publisher Name Bentham Science Publisher |
Online ISSN 2211-3533 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Human Tissue Kallikrein: A New Bullet for the Treatment of Ischemia
Current Pharmaceutical Design Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Dose HLA-B5, 7, 8, 27, and 51 Antigens Associated to Behcet's disease? A Study in Southwestern Iran
Current Rheumatology Reviews Therapeutic Drugs that Behave as Mechanism-Based Inhibitors of Cytochrome P450 3A4
Current Drug Metabolism T Cell Tuning for Tumour Therapy: Enhancing Effector Function and Memory Potential of Therapeutic T cells
Current Gene Therapy Transgenic Plants Expressing Bacterial Genes as a Model System for Plant Functional Genomics
Current Genomics Population-based Study of Risk Polymorphisms Associated with Vascular Disorders and Dementia
Current Genomics Enrichment of Up-regulated and Down-regulated Gene Clusters Using Gene Ontology, miRNAs and lncRNAs in Colorectal Cancer
Combinatorial Chemistry & High Throughput Screening The Role of Nitro (NO<sub>2</sub>-), Chloro (Cl), and Fluoro (F) Substitution in the Design of Antileishmanial and Antichagasic Compounds
Current Drug Targets Peripheral Arterial Disease: The Magnitude of the Problem and its Socioeconomic Impact
Current Drug Targets - Cardiovascular & Hematological Disorders Histamine and Histamine Receptor Antagonists in Cancer Biology
Inflammation & Allergy - Drug Targets (Discontinued) Editorial: [Monoclonal Antibodies in the Treatment of Asthma(Guest Editor: Moshe Ben-Shoshan)]
Recent Patents on Inflammation & Allergy Drug Discovery Modulation of Inflammation as a Way of Delaying Alzheimer's Disease Progression: The Diet's Role
Current Alzheimer Research Site-Selective, Chemical Modification of Protein at Aromatic Side Chain and Their Emergent Applications
Protein & Peptide Letters Surface-Linked Liposomal Antigen Induces IgE Selective Unresponsiveness in a T-Cell Independent Fashion
Current Drug Targets - Immune, Endocrine & Metabolic Disorders Candidiasis: A Fungal Infection- Current Challenges and Progress in Prevention and Treatment
Infectious Disorders - Drug Targets Bevacizumab for Malignant Brain Gliomas. Which is the Current Evidence?
Recent Patents on Inflammation & Allergy Drug Discovery Editorial [Hot Topic: Protective or Damaging Immunity in Infection (Guest Editors: Jose Gutierrez and Antonio Sorlozano)]
Current Immunology Reviews (Discontinued) Pigment Epithelium-Derived Factor Prevents Melanoma Growth via Angiogenesis Inhibition
Current Pharmaceutical Design Elevated Serum Human Cytomegalovirus IgM Levels in the Acute Phase of Ischemic Stroke are Associated with Increased Risk of Death and Major Disability
Current Neurovascular Research